Skip to main content
Top
Published in: Medical Microbiology and Immunology 3/2008

01-09-2008 | Rapid Communication

Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain)

Authors: Lluís Salleras, Àngela Domínguez, Pere Plans, Josep Costa, Neus Cardeñosa, Núria Torner, Antoni Plasència

Published in: Medical Microbiology and Immunology | Issue 3/2008

Login to get access

Abstract

The aim of this study was to determine the prevalence of varicella IgG antibodies in the population of Catalonia, and the variables associated. The study was carried out in 2002 in a representative sample of juvenile (5–14 years) and adult population (≥15 years) of Catalonia (Spain). The global prevalence determined by ELISA test was 95.5% (95% CI 94.7–96.3). The prevalence increased with age, from 82% (95% CI 77.0–87.0) in the 5–9 years age up to 99.4% (95% CI 98.2–100) in >64 years of age. No statistically significant differences in the seroprevalence according to the sociodemographic variables were observed. The current strategy of vaccinating preadolescents at 12 years of age who have not suffered the disease will require more than 30 years to cover the current gap immunity in adolescents and young adults. Vaccination with two doses of vaccine for all adolescents and adults ≤ 50 years who report not having suffered the disease during childhood should be considered.
Literature
2.
go back to reference Salleras L, Pujals JM, Salleras M (2003) Vacuna antivarizela-zoster. In: Salleras L (eds) Vacunaciones preventivas, 2nd edn. Masson, Barcelona, pp 311–330 Salleras L, Pujals JM, Salleras M (2003) Vacuna antivarizela-zoster. In: Salleras L (eds) Vacunaciones preventivas, 2nd edn. Masson, Barcelona, pp 311–330
3.
go back to reference Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. Med Microbiol Immunol 196:95–102PubMedCrossRef Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. Med Microbiol Immunol 196:95–102PubMedCrossRef
4.
go back to reference Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clinical Microbiol Rev 18:70–80CrossRef Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clinical Microbiol Rev 18:70–80CrossRef
5.
go back to reference Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science Limited, London Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science Limited, London
6.
go back to reference Office of Population Census and Surveys (1980) Classification of occupations. Office of Population Census, London Office of Population Census and Surveys (1980) Classification of occupations. Office of Population Census, London
7.
go back to reference Demmeler GJ, Steinberg SP, Blum G, Gershon AA (1988) A rapid enzyme-linked immunosorbent assay for detecting antibodies to varicella-zoster virus. J Infect Dis 157:211–212 Demmeler GJ, Steinberg SP, Blum G, Gershon AA (1988) A rapid enzyme-linked immunosorbent assay for detecting antibodies to varicella-zoster virus. J Infect Dis 157:211–212
8.
go back to reference Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19:183–188CrossRef Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19:183–188CrossRef
9.
go back to reference Wharton M (1996) The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am 10:571–581PubMedCrossRef Wharton M (1996) The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am 10:571–581PubMedCrossRef
10.
go back to reference Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22–25PubMed Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22–25PubMed
11.
go back to reference Pachón I, Amela C, de Ory F, León P, Alonso M (1998) Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996. Bol Epidemiol Semanal 6:93–104 Pachón I, Amela C, de Ory F, León P, Alonso M (1998) Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996. Bol Epidemiol Semanal 6:93–104
12.
go back to reference Gil A, González A, Dal-Ré R, Ortega P, Domínguez V (1998) Prevalence of antibodies against varicella zoster, Herpes simples (Types 1 and 2), hepatitis B and hepatitis A virases among Spanish adolescents. J Infect 36:53–6PubMedCrossRef Gil A, González A, Dal-Ré R, Ortega P, Domínguez V (1998) Prevalence of antibodies against varicella zoster, Herpes simples (Types 1 and 2), hepatitis B and hepatitis A virases among Spanish adolescents. J Infect 36:53–6PubMedCrossRef
13.
go back to reference Díez-Domingo J, Gil A, San-Martín M et al (2005) Seroprevalence of varicella among children and adolescents in Valencia, Spain: reliability of the parent’s reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccin 1:204–206PubMed Díez-Domingo J, Gil A, San-Martín M et al (2005) Seroprevalence of varicella among children and adolescents in Valencia, Spain: reliability of the parent’s reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccin 1:204–206PubMed
14.
go back to reference Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19:3097–3103PubMedCrossRef Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19:3097–3103PubMedCrossRef
15.
go back to reference Svahn A, Bergren J, Parke A, Storsaeter J, Thorstensson R, Linde A (2006) Changes in seroprevalence to four herpesvirus over 30 years in Swedish children aged 9–12 years. J Clin Virol 37:118–123PubMedCrossRef Svahn A, Bergren J, Parke A, Storsaeter J, Thorstensson R, Linde A (2006) Changes in seroprevalence to four herpesvirus over 30 years in Swedish children aged 9–12 years. J Clin Virol 37:118–123PubMedCrossRef
16.
go back to reference Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN (2007) Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 14:1057–1061PubMedCrossRef Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN (2007) Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 14:1057–1061PubMedCrossRef
17.
go back to reference Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:1214124PubMedCrossRef Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:1214124PubMedCrossRef
18.
go back to reference Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593PubMedCrossRef Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588–593PubMedCrossRef
19.
go back to reference Mossong J, Putz L, Schneider F (2004) Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 132:1121PubMedCrossRef Mossong J, Putz L, Schneider F (2004) Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 132:1121PubMedCrossRef
20.
go back to reference de Melker H, Berbers G, Hahne S et al (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946–3952PubMedCrossRef de Melker H, Berbers G, Hahne S et al (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946–3952PubMedCrossRef
21.
go back to reference Khoshnood B, Debruyne M, Lançon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41–44PubMedCrossRef Khoshnood B, Debruyne M, Lançon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41–44PubMedCrossRef
22.
go back to reference Gabuti G, Penna C, Rossi MA et al (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126:433–440CrossRef Gabuti G, Penna C, Rossi MA et al (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126:433–440CrossRef
23.
go back to reference Gürgöze MK, Yılmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akarsu S, Denizmen Aygün A (2006) Seroprevalence of mumps, varicella and rubella antibodies in children 1–16 years of age in eastern Turkey. Turk J Pediatr 48:185–188PubMed Gürgöze MK, Yılmaz E, Gödekmerdan A, Akça Z, Doğan Y, Akarsu S, Denizmen Aygün A (2006) Seroprevalence of mumps, varicella and rubella antibodies in children 1–16 years of age in eastern Turkey. Turk J Pediatr 48:185–188PubMed
24.
go back to reference Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007) Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr 96:861–863PubMedCrossRef Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007) Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr 96:861–863PubMedCrossRef
25.
go back to reference Breuer J (2004) Varicella zoster virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (eds) Principles and practice of clinical virology, 5th edn. Wiley, Chichester, pp 53–83CrossRef Breuer J (2004) Varicella zoster virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (eds) Principles and practice of clinical virology, 5th edn. Wiley, Chichester, pp 53–83CrossRef
26.
go back to reference Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006) Seroepidemiology of varicella zoster in Israel prior to large-scale use of varicella vaccines. Infection 34:208–213PubMedCrossRef Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006) Seroepidemiology of varicella zoster in Israel prior to large-scale use of varicella vaccines. Infection 34:208–213PubMedCrossRef
27.
go back to reference Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I et al (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866–7872PubMedCrossRef Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I et al (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866–7872PubMedCrossRef
28.
go back to reference Borras E, Domínguez A, Batalla J, Torner N, Cardeñosa N, Nebot M, Plasencia A, Salleras L (2007) Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25:3240–3243PubMedCrossRef Borras E, Domínguez A, Batalla J, Torner N, Cardeñosa N, Nebot M, Plasencia A, Salleras L (2007) Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25:3240–3243PubMedCrossRef
29.
go back to reference Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545PubMedCrossRef Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535–545PubMedCrossRef
30.
go back to reference Plans- Rubió P (2004) Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia (Spain). Vaccine 22:4002–4013PubMedCrossRef Plans- Rubió P (2004) Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia (Spain). Vaccine 22:4002–4013PubMedCrossRef
31.
go back to reference Plans P, Espuñes J, Plasencia A, Salleras L (2007) Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women childbearing age. Br J Obstet Gynaecol 114:122–127 Plans P, Espuñes J, Plasencia A, Salleras L (2007) Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women childbearing age. Br J Obstet Gynaecol 114:122–127
Metadata
Title
Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain)
Authors
Lluís Salleras
Àngela Domínguez
Pere Plans
Josep Costa
Neus Cardeñosa
Núria Torner
Antoni Plasència
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Medical Microbiology and Immunology / Issue 3/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-007-0064-z

Other articles of this Issue 3/2008

Medical Microbiology and Immunology 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.